UPDATE 1-Regulators flag possible birth defect link to GSK's HIV drug


U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018.



from Biotech News